TCGA-GD-A3OQ-01A-32R-A220-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.120893561
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.590
- G2M_CHECKPOINT+0.570
- MITOTIC_SPINDLE+0.530
- E2F_TARGETS+0.520
- MYC_TARGETS_V1+0.450
- NOTCH_SIGNALING+0.410
- PROTEIN_SECRETION+0.390
- TNFA_SIGNALING_VIA_NFKB+0.390
- UV_RESPONSE_DN+0.390
- ANDROGEN_RESPONSE+0.380
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.270
- KRAS_SIGNALING_DN-0.270
- PANCREAS_BETA_CELLS-0.270
- MYOGENESIS-0.260
- XENOBIOTIC_METABOLISM-0.150
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.110
- BILE_ACID_METABOLISM-0.080
- SPERMATOGENESIS-0.050
- HEDGEHOG_SIGNALING+0.000
- ANGIOGENESIS+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.874 |
| 2 | SRR9879279 | — | cohortA1 | 0.858 |
| 3 | 34229BDA-4BF2-4537-A663-15896F6E269A | — | — | 0.856 |
| 4 | SRR650183 | — | — | 0.849 |
| 5 | SRR934861 | — | — | 0.848 |
| 6 | TCGA-60-2710-01A-01R-0851-07 | — | cohortSQ2 | 0.845 |
| 7 | 8D30F824-25B9-43DB-BD39-2C9C790509DD | — | — | 0.841 |
| 8 | TCGA-FD-A3N5-01A-11R-A21D-07 | — | — | 0.837 |
| 9 | TCGA-34-8455-01A-11R-2326-07 | — | cohortSQ1 | 0.832 |
| 10 | SRR12696794 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.370 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |